The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone — are effective and save lives, but most people who could benefit from these treatments do not receive them, according to a report released today by the National Academies of Sciences, Engineering, and Medicine. Barriers to their use include stigma; inadequate professional education and training for treatment providers and criminal justice personnel; distinct treatment systems and financing mechanisms for OUD; regulations such as waiver policies, patient limits, and restrictions on treatment settings; privacy regulations such as 42 CFR Part 2; and regulations that govern public and private insurance coverage, the study committee said. The Substance Abuse and Mental Health Services Administration and National Institute on Drug Abuse sponsored the study.
 

Related News Articles

Headline
The Substance Abuse and Mental Health Services Administration will launch a three-part virtual learning series on recovery supports for people considering or…
Headline
Drug overdose deaths declined 5.1% in 2018 to about 68,000, according to preliminary data from the Centers for Disease Control and Prevention.
Headline
Under a new Centers for Medicare…
Headline
Six health care organizations in rural North Carolina communities will share $1.2 million in federal grant funds to strengthen and expand their response to…
Headline
The Food and Drug Administration yesterday released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic will host a free public webinar July 22 at 3 p.m. ET on best…